Amendment: Director Sandberg Richard A sold $70,506 worth of shares (12,000 units at $5.88) and bought $91,430 worth of shares (15,000 units at $6.10), decreasing direct ownership by 73% to 4,525 units (SEC Form 4)

$PRPO
Biotechnology: Laboratory Analytical Instruments
Industrials
Get the next $PRPO alert in real time by email
SEC FORM 4/A SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SANDBERG RICHARD A

(Last) (First) (Middle)
C/O PRECIPIO, INC.
4 SCIENCE PARK

(Street)
NEW HAVEN CT 06511

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Precipio, Inc. [ PRPO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/13/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
12/13/2024
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/13/2024 S 12,000 D $5.8755(1) 4,525(2) D
Common Stock 12/13/2024 P 15,000 A $6.0953(3) 19,525(2) I Roth IRA for the benefit of Richard A Sandberg
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.75 to $6.1804, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
2. In open market transactions, Mr. Sandberg decreased his personal holdings by 12,000 shares and simultaneously acquired 15,000 shares through a Roth IRA formed many years ago for his benefit, thereby effectively increasing the holdings in which he has a beneficial interest.
3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.90 to $6.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.
Remarks:
This amendment to the Form 4 originally filed on December 13, 2024 is being filed solely to include the range of prices for the reported transactions, as further described in footnotes 1 and 3 above.
/s/ Sandberg Richard 12/23/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $PRPO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PRPO

DatePrice TargetRatingAnalyst
More analyst ratings

$PRPO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Precipio Announces Q4 and year-end 2024 Shareholder Update Call

    NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10197585/fea81a2627 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in su

    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)

    NEW HAVEN, Conn., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that it has achieved two important financial goals in the last quarter of 2024: Positive Adjusted EBITDA – Precipio reports (unaudited) Adjusted EBITDA of $0.4M for Q4-2024. Adjusted EBITDA is a non-GAAP metric that comprises EBITDA, less non-cash stock-based compensation expense and other significant or non-operating (income) or expenses. Please see a detailed explanation at the bottom of this press release. Positive Cash flow. Precipio reports an (unaudited) increase of $0.3M in cash during Q4-2024. Of this improvement, $75,000 was due to directors' fees pai

    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs

    NEW HAVEN, Conn., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced that options granted to senior management on January 14 would vest when the 10-day VWAP of the Company's common stock exceeds $30.30 per share – a level 5x greater than the option exercise price, the closing price from Tuesday, January 14. These options have no time-based vesting; if the performance above is not met, the options will not vest. The Compensation Committee approved this form of vesting to incentivize the Company's senior management team to maximize the Company's performance and subsequent share price. The Compensation Committee provided the senio

    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$PRPO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PRPO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PRPO
SEC Filings

See more

$PRPO
Leadership Updates

Live Leadership Updates

See more
  • Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO

    NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that Mr. Carl Iberger, Precipio's CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, March 21st, 2022. Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis has been promoted to Interim Chief Financial Officer of the Company effective immediately. Mr. Gage joined Precipio following its acquisition of Transgenomic in July of 2017. He has worked closely with Mr. Ib

    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • 89bio Announces Appointment of Kathy LaPorte to its Board of Directors

    SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien

    $BOLT
    $ETNB
    $PRPO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors

    NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his role as a Director on the company’s board. Mr. Sandberg has been involved with Precipio since its inception and has acted in various advisory roles. in 2019 he joined the company’s Board of Directors and has been a significant contributor to helping the company formulate strategy and execute on its plans. Mr Sandberg is a seasoned diagnostics executive with a substantial track record in the field of diagnostics. As the f

    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$PRPO
Financials

Live finance-specific insights

See more
  • Precipio Announces Q4 and year-end 2024 Shareholder Update Call

    NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10197585/fea81a2627 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in su

    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)

    NEW HAVEN, Conn., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that it has achieved two important financial goals in the last quarter of 2024: Positive Adjusted EBITDA – Precipio reports (unaudited) Adjusted EBITDA of $0.4M for Q4-2024. Adjusted EBITDA is a non-GAAP metric that comprises EBITDA, less non-cash stock-based compensation expense and other significant or non-operating (income) or expenses. Please see a detailed explanation at the bottom of this press release. Positive Cash flow. Precipio reports an (unaudited) increase of $0.3M in cash during Q4-2024. Of this improvement, $75,000 was due to directors' fees pai

    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Precipio Announces Q3-2024 Shareholder Update Call

    Conference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q3-2024 corporate update call on November 18th at 5:00 PM ET. The call will provide commentary on Precipio's Q3-2024 10-Q filed today, including financial highlights and analysis of the company's core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10194411/fdf400

    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$PRPO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more